Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17724493 | 1.00 | CYP2D6 (0.46) | CYP2D6SRCALDH1A1CYP3A4LMNA | |
| SCHEMBL24327749 | 1.00 | CYP2D6 (0.46) | CYP2D6SRCALDH1A1CYP3A4LMNA | |
| SCHEMBL8400939 | 0.87 | SRC (0.54) | CYP2D6SRCALDH1A1CYP3A4LMNA | |
| SCHEMBL18908323 | 0.86 | CYP3A4 (0.49) | CYP2D6SRCALDH1A1CYP3A4LMNA | |
| SCHEMBL13554104 | 0.86 | CYP3A4 (0.49) | CYP2D6SRCALDH1A1CYP3A4LMNA | |
| SCHEMBL13554080 | 0.86 | CYP3A4 (0.49) | CYP2D6SRCALDH1A1CYP3A4LMNA | |
| SCHEMBL24327746 | 0.84 | KEAP1 (0.46) | ALDH1A1LMNAPTGS2 | |
| SCHEMBL22758082 | 0.84 | ALOX5 (0.46) | CYP2D6SRCALDH1A1CYP3A4LMNA | |
| SCHEMBL24327735 | 0.82 | NPSR1 (0.41) | ALDH1A1LMNAPPARAPPARGPTGS1 | |
| SCHEMBL24327742 | 0.82 | PPARG (0.50) | CYP2D6ALDH1A1PPARAKMT2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3214086-B1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| CN-108165438-A | A kind of preparation method of hidden effect resveratrol white wine | 王德福 | 2018-06-15 | — | — | CN | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| EP-2766352-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (UHN) (CA) | 2014-08-20 | — | — | EP | disclosed |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERISTY HEALTH NETWORKS (CA) | 2014-02-20 | — | — | US | disclosed |
| US-6020343-A | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors | MERCK FROSST CANADA, INC. (CA) | 2000-02-01 | — | — | US | disclosed |
| US-5998444-A | ANTIASTHMA AGENTS; NEUROKININ ANTAGONIST | ZENECA LTD. (GB) | 1999-12-07 | — | — | US | disclosed |
| US-5981576-A | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors | MERCK FROSST CANADA, INC. (CA) | 1999-11-09 | — | — | US | disclosed |
| EP-0904269-A1 | 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-03-31 | — | — | EP | disclosed |
| US-5855971-A | Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film | NIPPON OIL COMPANY, LIMITED (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | disclosed |
| US-5698584-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1997-12-16 | — | — | US | disclosed |
| WO-1997016435-A1 | 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | disclosed |
| EP-0758013-A1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | CYP2D6 96/4885SRC 1899/4885ALDH1A1 66/4885 |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | CYP2D6 3151/4885SRC 508/4885ALDH1A1 2934/4885 |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K7, MAP3K1, MAP3K20 | CYP2D6 3141/4885SRC 44/4885ALDH1A1 2710/4885 |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | CYP2D6 96/4885SRC 1899/4885ALDH1A1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.